The medical website on June 1, pediatrics (child) medicine has been in short supply at home and abroad. In our country, the situation is more serious, there has been "the medicine depends on the guess, the measurement relies on the" phenomenon, this also shows the severe fact that the child medicine is short on the other level. Recently, the paediatric medicine has encouraged the policy to be more frequent, on children's day this day we came to 818 which drug companies have the "money" way? 

 

▍ frequent encouragement policy, pediatric (child) medicine development opportunity 

 

Total bureau of national health development planning commission and the food and drug supervision and administration on May 12, released on May 18, such as "about the second batch of encouraging r&d publication of the declaration for the children's medicine suggested list" and "adult medicine data extrapolation to the pediatric population technical guiding principles and policies, to enrich children is suitable for drug variety, dosage forms and specifications, meet the demand of pediatric clinical drug use. Guidance is given in the development of the market to promote the development of pediatrics. 

 

In fact, paediatric drugs have been the focus of national policy in recent years. 

 

In June 2011, the state council executive meeting of the "Chinese children development compendium (2011-2020)", to solve the problem of shortage of children's drugs target set ten years, encourage children's drug research and development and production, expanding the national list of essential medicines in pediatric drug varieties and dosage form, improve the children's drugs directory, put forward in the legislation law. 

 

The provision, policy planning and the allocation of public resources will give priority to the interests and needs of children and maximize the benefits of children. This is the first time the state council has proposed legislation to promote the adoption of medicines for children. 

 

Especially since 2014, when the development planning commission, the ministry of six ministries jointly issued "several opinions about guarantee children's drugs, all kinds of articles, policies related to children's medicine to be published in newspapers frequently, mesh side, further arouse people's attention. Issued by the national related departments in succession in 2016 "about clinical medicine for children need to apply for priority review approval varieties to assess basic principle and the announcement of the first priority review of varieties of, the research and development of the first batch of encouraging declaration for the children's medicine suggestion list and other documents. 

 

▍ mainly in pediatrics (children's) drug firms lists basic financial indicators 

 

Among the 10 major paediatric medicines in China, there are among the 10 companies that have the old name, such as the jianmin group, etc. There are also new medical players like sanli pharmaceuticals. 

 

These companies have annual sales of more than billions, net profit in more than 1 billion yuan of large enterprise groups, such as baiyun mountain, also have annual income below 500 million or net profit in less than fifty million yuan of small and medium enterprises, such as Kang Zhi pharmaceutical, talc pharmaceutical industry. 

 

The list of the top 10 drug companies is the following: 

 

Note: the data is derived from each company's annual report. The ranking of revenue in 2016. 

 

▍ mainly in pediatrics (children's) medicine enterprise strength than the rating 

 

Of the 10 pharmaceutical companies, the paediatric drug sales are at more than 200 million yuan. 

 

Among them, the largest drug firms is the sunflower pharmaceutical, operating income, according to the annual report in 1.5 billion yuan, calculated and second Harbin pharmaceutical shares in pediatrics (children's) also relies on its market share in the field of calcium in liquid recorded nearly 1.4 billion yuan of business revenue. 

 

In terms of the proportion of the business income of these enterprises, the four companies, such as sanli pharmaceutical, kangzhi pharmaceuticals and sanhuatu, are more than 50 per cent. 

 

In terms of growth, there has been a significant increase in the number of companies such as kangzhi pharmaceuticals, sanli pharmaceutical, and zichuan pharmaceutical, and there have been significant declines in the pharmaceutical industry. 

 

The list of 10 drug companies' earnings is as follows: 

 

Note: the data is derived from the annual report of various companies for reference. The ranking of the business income of paediatric medicine in 2016. Sunflower pharmaceutical, baiyun mountain, sunny pharmaceutical enterprise, announced the river on the pharmaceutical industry has not been clear in pediatrics (children's) drug revenue data, the data in the table according to the enterprise annual report listing prospectus, speculation and, for your reference. 

 

Sunflower pharmaceuticals 

 

Company products are mainly layout children's drugs, the digestive system drugs, breathing cold medication, medication, rheumatism bone disease of department of gynaecology drugs, cardiovascular drugs, six big products group. 

 

Children's drugs mainly have children lungs heat to cough and gasp the oral liquid, infantile Indian bay leaf particles, fever, infantile acetaminophen yellow that sensitive particles, infantile phlegm cough particles, infantile lung phlegm particles, including children lungs heat to cough and gasp the oral liquid and particle, sales income in 300 million yuan of above. 

 

In marketing, the company has successfully held the first child safety drug transmission and development conference in 2016. "The child is not your shrink, the child wants to use the child medicine!" The publicity has deepened the popularity of the brand and expanded the brand influence of small sunflower children's medicines. 

 

The five products of enterprise children's medicine are six types of drugs: 

 

It is used in children's foreign febrile fever, with fever, aching head, nose, thirst, red and yellow, etc. We are currently in the preliminary phase of clinical trial. 

 

Wood pediatric pneumonia (2) the gold particles, for children from the six evils of the exogenous, plague poison, toxic heat accumulate lung, qi depression indicates, sputum XuanSu disadvantage caused by fever, cough, wheeze, shortness of breath, be agitated, coughing up phlegm and other symptoms. We are currently in the preliminary phase of clinical trial. 

 

The children's vitamin D chews are used to supplement children's calcium. It is currently under review and review by the state food and drug administration. 

 

It is used for calcium supplement for children. It is currently under review and review by the state food and drug administration. 

 

It is an oral solution for children common cold or influenza. It is currently under review and review by the state food and drug administration. 

 

halon 

 

The shares of Harbin pharmaceutical are in line with the market changes in the pharmaceutical industry, pushing forward the marketing reform and accelerating the adjustment of the product structure. The company proactively promotes the "franchised model" and ADAPTS to the requirement of the national health reform policy in advance. 

 

Points in the whole country, regional monopoly, the reserved agreement "signed by both parties to the contractual constraints management, contract for cash sales, industrial products and give the Harbin pharmaceutical products all the only franchise in the region. 

 

Company's "specializing in a model" has achieved sales terminals can be controlled, the preliminary effect such as consumer drug safety can be guaranteed, marketing advantage continuously emerging, provide effective support to improve the company's market competitiveness. 

 

The specific measures taken include: 

 

The system of marketing evaluation, which is centered on profit assessment, is formulated and the plan of evaluation is formulated. 

 

Through specialized network construction, compressed channel level, integrated resources input, and exert advantageous resource synergy effect, reasonable control of sales expenses; 

 

(3) to actively adjust the product marketing strategy for products to stop production loss without market prospect, for loss of products with market prospects to limit production limit pin, emphatically promoted lacidipine plain radiographs, restructuring and promote red injection, zinc gluconate, calcium gluconate oral solution oral liquid, leading to injection, children acetaminophen yellow that sensitive particles such as the point scale advantage product sales. 

 

sandahua 

 

The children's medicine of the mountain is mainly operated by its subsidiary, dachin. 

 

Children's medicine mainly including vitamin AD drops (new), compound calcium carbonate effervescent granules (cover) flute hin, licorice zinc particles GanXin (Iraq), azithromycin granules, rifampicin and wast, and Ming dry suspension agent, two sh succinic acid capsules, etc., among them, can be "new" for the national well-known trademark, the years have been the first among similar products market share. In 2016, the company has moved into the mother-to-child market with the advantage of the "yixin" brand, which will further accelerate the distribution of children's health. 

 

Dyne pharmaceutical drug research and development strategy for implementing customized children, realize the strategic target of the company become the industry leader, set up Beijing dyne high-tech medicines for children research institute co., LTD., relying on Beijing region, talent advantage, in order to much starker choices-and graver consequences-in new drugs major initiative as an opportunity to build platform for the domestic first-class high-end professional children's drugs preparations. 

 

The current program for drug registrations in the pharmaceutical industry is all children's medicines. A clinical trial has been carried out for the multipanlidone suspension, which is completed in 2016. 

 

At the same time, the new coke determination tablet, the dichlorrethane, the oral solution, the clinical trial of the dipperate and the granule; To obtain the notification of the notification of the two products of pedomodore oral liquid and montmorillonite. Currently, five r&d projects are in line for review. 

 

Kangzhi pharmaceuticals 

 

Kang Zhi pharmaceutical industry focus on children's health, dedicated to the children in the field of drug research and development, production and sales, and always adhere to the "do medical products, professional market" business philosophy, to science and technology as the power, can strengthen children's medicine industry. 

 

Kang Zhi pharmaceutical sales of children's products already on the market has formed a relatively complete product group, such as children's series, the series of children's cold fever, diarrhea in children with digestive series, children's cough phlegm series, children's resistance to infection, nutritional supplements. 

 

Company mainly around the high-quality goods strategy, children's health strategy, adhering to the principle of win-win cooperation under the agent system, and through elaborating China merchants and strict control pin, dominated by the product manager, on the basis of academic and aimed at the whole channel marketing model. At present, the company has established a mature marketing cooperation model, and the marketing network has been covered in all provinces and cities, and the county level is 90%. 

 

Company in research and development of new drug project at the same time, actively to the secondary development of production of products, developed by improving the taste and is suitable for children dosage forms, such as technology research to improve customer satisfaction, product standards and reduced cost of production, such as strategy, in order to enhance the competitiveness of the company's main varieties. 

 

▍ pediatrics (children's) big medicine "money" way 

 

China as the 2016 "comprehensive two children" policy, more and more doctors and parents recognized children medicine "medicine cure" advantage, it will certainly bring children medicine niche forecast of explosive growth. According to China's sixth census, China has more than 220 million children aged between 0 and 14, accounting for 16.6 percent of the total population. 

 

As the "comprehensive two-child" policy is fully relaxed, the proportion of children will increase in the coming years. Demand of clinic will directly stimulate children's medicine market's overall growth, rising market demand for children's medicine and related policy dividend developed, will be for children, provide powerful guarantee the stability of the medicine industry sustainable development. 

 

According to the public information, the market for pediatric medicine in China was 1,20820 million yuan in 2015, a year-on-year increase of 9.3%, and the author's conservative estimate has exceeded 130 billion yuan in 2016. 

 

"Two-child policy" full liberalisation will prompt for fourth baby boom in China, children's population will continue to grow over the next ten years, until 2024, when children population proportion is expected to reach 18.3%, about 265 million. With a variety of positive policies, the market for children's medicines is expected to continue to grow at a high rate. 

 

The time has come for the rapid development of paediatric medicine. Will you be ready for future "money"?